RETEVMO 80 MG
SELPERCATINIB : 80 MG · DIN 02516926 · LOXO ONCOLOGY INC
Health Canada status: MARKETED
What is RETEVMO?
RETEVMO 80 MG contains SELPERCATINIB : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02516926, held by LOXO ONCOLOGY INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 06-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RETEVMO used for?
Metastatic RET fusion-positive NSCLC (adults); RET-mutant medullary thyroid cancer (adults/pediatrics ≥12y); RET fusion-positive differentiated thyroid carcinoma (adults) after prior therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02516926 |
|---|---|
| Brand name | RETEVMO |
| Generic / active ingredient | SELPERCATINIB : 80 MG |
| Manufacturer | LOXO ONCOLOGY INC |
| Strength | 80 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EX22 SELPERCATINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Nov-2025 |
| Original market date | 2022-01-21 00:00:00 |
How is it administered?
Based on weight: <50 kg: 120 mg BID; ≥50 kg: 160 mg BID. Administer orally every 12 hours. Dose reductions required for severe hepatic impairment (80 mg BID) and adverse reactions.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard section 11 mentioned in TOC but text cuts off).
How is it supplied?
40 mg: Bottles of 60 capsules. 80 mg: Bottles of 60 or 120 capsules.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Warnings and precautions
Serious warnings: Embryo-fetal toxicity, hemorrhage, hepatotoxicity, hypersensitivity, hypertension, ILD/pneumonitis, and QTc interval prolongation. Impaired wound healing risk.
What can be used instead?
Other Canadian products sharing ATC code L01EX22 SELPERCATINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RETEVMO | 40 MG | CAPSULE | LOXO ONCOLOGY INC | MARKETED | DIN 02516918 |
Who else supplies SELPERCATINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SELPERCATINIB appears in 32 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.